September 9, 2020
Cerenovus Launches Suite of Technologies to Treat Stroke
September 9, 2020—Cerenovus, part of Johnson & Johnson Medical Devices Companies, announced that it has launched Cerenovus Stroke Solutions, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the European Society of Minimally Invasive Neurological Therapy’s ESMINT Congress 2020, held as a virtual meeting September 9-10.
According to the company, the Cerenovus Stroke Solutions suite of devices for mechanical thrombectomy procedures includes:
- Cerebase DA, a long guide sheath designed to navigate challenging anatomy and secure distal access for geometric anchoring
- Cerenovus large-bore catheter, which is designed for atraumatic vessel wall interaction and allows rapid navigation to the middle cerebral artery
- Embotrap III, the company’s latest-generation stent retriever, a revascularization device designed to engage a wide range of clot types and provide tailored options to achieve the First Pass Effect (FPE); the company noted that FPE is an independent predictor of good functional outcome and has resulted in faster patient recovery times
Also at ESMINT, the company advised that interim data from the EXCELLENT registry were presented. The data focused on the composition of clots collected in the registry. The company uses the findings on clot composition to inform the design of Cerenovus Stroke Solutions devices. The Principal Investigator of the EXCELLENT study is Professor Kyriakos Lobotesis, MD, with Imperial College Healthcare NHS Trust in London, United Kingdom.
“Not all mechanical thrombectomy procedures are equal, and the greatest benefits to patients are observed when reperfusion is achieved from the first pass,” commented Prof. Lobotesis in the company’s announcement. “The EXCELLENT registry is a unique study that goes beyond reporting patient outcomes and helps to understand more about clot composition, revascularization rates, and clinical outcomes.”